Overview

Treatment With Ambrisentan in Patients With Borderline Pulmonary Arterial Hypertension

Status:
Not yet recruiting
Trial end date:
2026-03-30
Target enrollment:
Participant gender:
Summary
An Investigator initiated trial (IIT) using a prospective, randomized, double-blind, parallel group, placebo-controlled, clinical study design.
Phase:
N/A
Details
Lead Sponsor:
Nanjing First Hospital, Nanjing Medical University
Collaborator:
Tianjin Medical University General Hospital
Treatments:
Ambrisentan